Literature DB >> 18177580

Resistant hypertension and aldosteronism.

Eduardo Pimenta1, David A Calhoun.   

Abstract

Resistant hypertension is defined as blood pressure that remains uncontrolled despite using at least three antihypertensive medications in effective doses, ideally including a diuretic. Stricter blood pressure goals, higher obesity rates, older age, and increased use of certain exogenous substances are related to an increasing prevalence of resistant hypertension. The evaluation of patients with resistant hypertension focuses on identifying contributing factors and secondary causes of hypertension including hyperaldosteronism, obstructive sleep apnea, renal artery stenosis, and pheochromocytoma. Hyperaldosteronism is now recognized as the most common secondary cause and all patients with resistant hypertension should be screened with a plasma aldosterone-renin ratio even if the serum potassium level is normal. Treatment includes reversal of contributing factors, appropriate treatment of secondary causes, and use of effective multidrug regimens. Recent studies indicate that the addition of spironolactone to standard treatment regimens induces significant blood pressure reduction in patients with resistant hypertension.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18177580     DOI: 10.1007/s11906-007-0066-7

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  34 in total

1.  Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio.

Authors:  B J Gallay; S Ahmad; L Xu; B Toivola; R C Davidson
Journal:  Am J Kidney Dis       Date:  2001-04       Impact factor: 8.860

2.  Hyperaldosteronism among black and white subjects with resistant hypertension.

Authors:  David A Calhoun; Mari K Nishizaka; Mohammad A Zaman; Roopal B Thakkar; Paula Weissmann
Journal:  Hypertension       Date:  2002-12       Impact factor: 10.190

3.  Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension.

Authors:  Mari K Nishizaka; Monique Pratt-Ubunama; Mohammad A Zaman; Stacey Cofield; David A Calhoun
Journal:  Am J Hypertens       Date:  2005-06       Impact factor: 2.689

4.  Low-dose spironolactone in the management of resistant hypertension: a surveillance study.

Authors:  Deirdre A Lane; Sarah Shah; D Gareth Beevers
Journal:  J Hypertens       Date:  2007-04       Impact factor: 4.844

5.  Changes in left ventricular anatomy and function in hypertension and primary aldosteronism.

Authors:  G P Rossi; A Sacchetto; P Visentin; C Canali; G R Graniero; P Palatini; A C Pessina
Journal:  Hypertension       Date:  1996-05       Impact factor: 10.190

6.  Resistant hypertension revisited: a comparison of two university-based cohorts.

Authors:  Jay P Garg; William J Elliott; Amy Folker; Munavvar Izhar; Henry R Black
Journal:  Am J Hypertens       Date:  2005-05       Impact factor: 2.689

7.  Aldosterone induces a vascular inflammatory phenotype in the rat heart.

Authors:  Ricardo Rocha; Amy E Rudolph; Gregory E Frierdich; Denise A Nachowiak; Beverly K Kekec; Eric A G Blomme; Ellen G McMahon; John A Delyani
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-11       Impact factor: 4.733

8.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

9.  Mineralocorticoid excess, dietary sodium, and myocardial fibrosis.

Authors:  C G Brilla; K T Weber
Journal:  J Lab Clin Med       Date:  1992-12
View more
  19 in total

1.  Na+-sensitive elevation in blood pressure is ENaC independent in diet-induced obesity and insulin resistance.

Authors:  Jonathan M Nizar; Wuxing Dong; Robert B McClellan; Mariana Labarca; Yuehan Zhou; Jared Wong; Donald G Goens; Mingming Zhao; Nona Velarde; Daniel Bernstein; Michael Pellizzon; Lisa M Satlin; Vivek Bhalla
Journal:  Am J Physiol Renal Physiol       Date:  2016-02-03

Review 2.  Drug therapy of apparent treatment-resistant hypertension: focus on mineralocorticoid receptor antagonists.

Authors:  Daniel Glicklich; William H Frishman
Journal:  Drugs       Date:  2015-04       Impact factor: 9.546

Review 3.  Clinical Diagnosis and Management of Resistant Hypertension.

Authors:  Costas P Tsioufis; Alexandros Kasiakogias; Dimitrios Tousoulis
Journal:  Eur Cardiol       Date:  2016-08

4.  Mood Disorders in Uncontrolled Hypertension Despite Multiple Anti-Hypertensive Medications: Searching for a Link.

Authors:  Alberto Mazza; Roberta Ravenni; Michela Armigliato; Ciro Rossetti; Laura Schiavon; Fulvio Fiorini; Gianluca Rigatelli; Emilio Ramazzina; Edoardo Casiglia
Journal:  High Blood Press Cardiovasc Prev       Date:  2016-01-04

Review 5.  Incident ESRD and treatment-resistant hypertension: the reasons for geographic and racial differences in stroke (REGARDS) study.

Authors:  Rikki M Tanner; David A Calhoun; Emmy K Bell; C Barrett Bowling; Orlando M Gutiérrez; Marguerite R Irvin; Daniel T Lackland; Suzanne Oparil; William McClellan; David G Warnock; Paul Muntner
Journal:  Am J Kidney Dis       Date:  2014-01-01       Impact factor: 8.860

6.  Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008.

Authors:  Brent M Egan; Yumin Zhao; R Neal Axon; Walter A Brzezinski; Keith C Ferdinand
Journal:  Circulation       Date:  2011-08-08       Impact factor: 29.690

Review 7.  Sympathetic neural mechanisms in human hypertension.

Authors:  Ronald G Victor; Moiz M Shafiq
Journal:  Curr Hypertens Rep       Date:  2008-06       Impact factor: 5.369

8.  Brazilian Position Statement on Resistant Hypertension - 2020.

Authors:  Juan Carlos Yugar-Toledo; Heitor Moreno Júnior; Miguel Gus; Guido Bernardo Aranha Rosito; Luiz César Nazário Scala; Elizabeth Silaid Muxfeldt; Alexandre Alessi; Andrea Araújo Brandão; Osni Moreira Filho; Audes Diógenes de Magalhães Feitosa; Oswaldo Passarelli Júnior; Dilma do Socorro Moraes de Souza; Celso Amodeo; Weimar Kunz Sebba Barroso; Marco Antônio Mota Gomes; Annelise Machado Gomes de Paiva; Eduardo Costa Duarte Barbosa; Roberto Dischinger Miranda; José Fernando Vilela-Martin; Wilson Nadruz Júnior; Cibele Isaac Saad Rodrigues; Luciano Ferreira Drager; Luiz Aparecido Bortolotto; Fernanda Marciano Consolim-Colombo; Márcio Gonçalves de Sousa; Flávio Antonio de Oliveira Borelli; Sérgio Emanuel Kaiser; Gil Fernando Salles; Maria de Fátima de Azevedo; Lucélia Batista Neves Cunha Magalhães; Rui Manoel Dos Santos Póvoa; Marcus Vinícius Bolívar Malachias; Armando da Rocha Nogueira; Paulo César Brandão Veiga Jardim; Thiago de Souza Veiga Jardim
Journal:  Arq Bras Cardiol       Date:  2020 May-Jun       Impact factor: 2.000

Review 9.  Controlled Versus Uncontrolled Resistant Hypertension: Are They in the Same Bag?

Authors:  J C Yugar-Toledo; V Brunelli; J F Vilela-Martin; A Fattori; H Moreno
Journal:  Curr Hypertens Rep       Date:  2018-03-27       Impact factor: 5.369

Review 10.  The growing epidemic of hypertension among children and adolescents: a challenging road ahead.

Authors:  Farahnak Assadi
Journal:  Pediatr Cardiol       Date:  2012-05-08       Impact factor: 1.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.